{"pmid":32432127,"pmcid":"PMC7214683","title":"COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2.","text":["COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2.","The COVID-19 pandemic is an unprecedented challenge and will require novel therapeutic strategies. Affected patients are likely to be at risk of arrhythmia due to underlying comorbidities, polypharmacy and the disease process. Importantly, a number of the medications likely to receive significant use can themselves, particularly in combination, be pro-arrhythmic. Drug-induced prolongation of the QT interval is primarily caused by inhibition of the hERG potassium channel either directly and/or by impaired channel trafficking. Concurrent use of multiple hERG-blocking drugs may have a synergistic rather than additive effect which, in addition to any pre-existing polypharmacy, critical illness or electrolyte imbalance, may significantly increase the risk of arrhythmia and Torsades de Pointes. Knowledge of these risks will allow informed decisions regarding appropriate therapeutics and monitoring to keep our patients safe.","Front Cardiovasc Med","Carpenter, Alexander","Chambers, Owen J","El Harchi, Aziza","Bond, Richard","Hanington, Oliver","Harmer, Stephen C","Hancox, Jules C","James, Andrew F","32432127"],"abstract":["The COVID-19 pandemic is an unprecedented challenge and will require novel therapeutic strategies. Affected patients are likely to be at risk of arrhythmia due to underlying comorbidities, polypharmacy and the disease process. Importantly, a number of the medications likely to receive significant use can themselves, particularly in combination, be pro-arrhythmic. Drug-induced prolongation of the QT interval is primarily caused by inhibition of the hERG potassium channel either directly and/or by impaired channel trafficking. Concurrent use of multiple hERG-blocking drugs may have a synergistic rather than additive effect which, in addition to any pre-existing polypharmacy, critical illness or electrolyte imbalance, may significantly increase the risk of arrhythmia and Torsades de Pointes. Knowledge of these risks will allow informed decisions regarding appropriate therapeutics and monitoring to keep our patients safe."],"journal":"Front Cardiovasc Med","authors":["Carpenter, Alexander","Chambers, Owen J","El Harchi, Aziza","Bond, Richard","Hanington, Oliver","Harmer, Stephen C","Hancox, Jules C","James, Andrew F"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32432127","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3389/fcvm.2020.00085","keywords":["covid-19","qt","qtc","arrhythmia","drug safety","herg"],"topics":["Treatment"],"weight":1,"_version_":1667342288367386624,"score":9.490897,"similar":[{"pmid":32463308,"title":"Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?","text":["Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?","The SARS-Cov-2 viral pandemic causing COVID-19 disease begs for rapid and innovative treatments. In addition to flu-like respiratory symptoms, acute cardiac manifestations include cardiac injury, shock and arrhythmia. Several pharmacological therapies have been suggested including repurposing of existing drugs such as chloroquine and hydroxychloroquine, sometimes co-administered with azithromycin. Chloroquine and hydroxychloroquine were developed in the World War II era for treatment and prophylaxis of malaria, long before modern drug safety surveillance programs. Clinically they can prolong the QT interval to potentially initiate ventricular arrhythmias including torsades de pointes, and also cause QRS widening. Chloroquine interacts with multiple cardiac ion channels including the hERG potassium channel that is essential for normal electrical activity in the heart. A reduction in hERG channel potassium current is the principle cause of drug-induced long QT syndrome. Azithromycin also can cause modest QT interval prolongation, but not through potent hERG channel blockade, rather when used chronically through an increase in peak and late cardiac sodium current to cause potential loading of cardiomyocytes with sodium and calcium to produce calcium overload. How should we proceed with the use of chloroquine and hydroxychloroquine, potentially combined with azithromycin, for COVID-19 given that these agents bring some cardiac toxicity risk and their mechanisms for cardiac toxicity may not be the same? Is combining different and potentially additive mechanisms of cardiotoxicity wise? How great the risk is relative to the benefit in critically ill COVID-19 patients will need to await the outcome of ongoing, controlled clinical trials.","J Am Heart Assoc","Kamp, Timothy J","Hamdan, Mohamed H","January, Craig T","32463308"],"abstract":["The SARS-Cov-2 viral pandemic causing COVID-19 disease begs for rapid and innovative treatments. In addition to flu-like respiratory symptoms, acute cardiac manifestations include cardiac injury, shock and arrhythmia. Several pharmacological therapies have been suggested including repurposing of existing drugs such as chloroquine and hydroxychloroquine, sometimes co-administered with azithromycin. Chloroquine and hydroxychloroquine were developed in the World War II era for treatment and prophylaxis of malaria, long before modern drug safety surveillance programs. Clinically they can prolong the QT interval to potentially initiate ventricular arrhythmias including torsades de pointes, and also cause QRS widening. Chloroquine interacts with multiple cardiac ion channels including the hERG potassium channel that is essential for normal electrical activity in the heart. A reduction in hERG channel potassium current is the principle cause of drug-induced long QT syndrome. Azithromycin also can cause modest QT interval prolongation, but not through potent hERG channel blockade, rather when used chronically through an increase in peak and late cardiac sodium current to cause potential loading of cardiomyocytes with sodium and calcium to produce calcium overload. How should we proceed with the use of chloroquine and hydroxychloroquine, potentially combined with azithromycin, for COVID-19 given that these agents bring some cardiac toxicity risk and their mechanisms for cardiac toxicity may not be the same? Is combining different and potentially additive mechanisms of cardiotoxicity wise? How great the risk is relative to the benefit in critically ill COVID-19 patients will need to await the outcome of ongoing, controlled clinical trials."],"journal":"J Am Heart Assoc","authors":["Kamp, Timothy J","Hamdan, Mohamed H","January, Craig T"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32463308","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1161/JAHA.120.016887","keywords":["cardiotoxicity","drug therapy","long qt syndrome"],"locations":["Hydroxychloroquine"],"e_drugs":["Potassium","Sodium","Chloroquine","Hydroxychloroquine","Azithromycin","Calcium"],"topics":["Treatment"],"weight":1,"_version_":1668079521443610624,"score":474.18018},{"pmid":32438018,"title":"QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review.","text":["QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review.","Chloroquine and hydroxychloroquine are now being widely used as treatments for COVID-19. Both medications prolong the QT interval and accordingly may put patients at increased risk of torsades de pointes and sudden death. Published guidance documents vary in their recommendations for monitoring and managing these potential adverse effects. Accordingly, we set out to conduct a systematic review of the arrhythmogenic effect of short courses of chloroquine or hydroxychloroquine. We searched in MEDLINE and Embase, as well as grey literature up to April 17, 2020, on the risk of QT prolongation, torsades, ventricular arrhythmia, and sudden death with short-term chloroquine and hydroxychloroquine usage. This resulted in 390 unique records, of which fourteen were ultimately selected for qualitative synthesis and which included data on 1515 COVID-19 patients. Approximately 10% of COVID-19 patients treated with these drugs developed QT prolongation. We found evidence of ventricular arrhythmia in two COVID-19 patients out of a group of 28 treated with high-dose chloroquine. A limitation of these results is unclear follow-up and possible publication/reporting bias, but there is compelling evidence that chloroquine and hydroxychloroquine induce significant QT interval prolongation and potentially increase the risk of arrhythmia. Daily ECG monitoring and other risk mitigation strategies should be considered in order to prevent possible harms from what is currently an unproven therapy.","Heart Rhythm","Jankelson, Lior","Karam, Giorgio","Becker, Matthijs L","Chinitz, Larry A","Tsai, Meng-Chiao","32438018"],"abstract":["Chloroquine and hydroxychloroquine are now being widely used as treatments for COVID-19. Both medications prolong the QT interval and accordingly may put patients at increased risk of torsades de pointes and sudden death. Published guidance documents vary in their recommendations for monitoring and managing these potential adverse effects. Accordingly, we set out to conduct a systematic review of the arrhythmogenic effect of short courses of chloroquine or hydroxychloroquine. We searched in MEDLINE and Embase, as well as grey literature up to April 17, 2020, on the risk of QT prolongation, torsades, ventricular arrhythmia, and sudden death with short-term chloroquine and hydroxychloroquine usage. This resulted in 390 unique records, of which fourteen were ultimately selected for qualitative synthesis and which included data on 1515 COVID-19 patients. Approximately 10% of COVID-19 patients treated with these drugs developed QT prolongation. We found evidence of ventricular arrhythmia in two COVID-19 patients out of a group of 28 treated with high-dose chloroquine. A limitation of these results is unclear follow-up and possible publication/reporting bias, but there is compelling evidence that chloroquine and hydroxychloroquine induce significant QT interval prolongation and potentially increase the risk of arrhythmia. Daily ECG monitoring and other risk mitigation strategies should be considered in order to prevent possible harms from what is currently an unproven therapy."],"journal":"Heart Rhythm","authors":["Jankelson, Lior","Karam, Giorgio","Becker, Matthijs L","Chinitz, Larry A","Tsai, Meng-Chiao"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32438018","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.hrthm.2020.05.008","keywords":["covid-19","sars-cov-2","arrhythmia","chloroquine","coronavirus","hydroxychloroquine","sudden death","torsades de pointes"],"e_drugs":["Chloroquine","Hydroxychloroquine"],"topics":["Treatment"],"weight":1,"_version_":1667521393823055872,"score":289.41074},{"pmid":32387247,"title":"ENHANCED ECG MONITORING OF COVID-19 PATIENTS.","text":["ENHANCED ECG MONITORING OF COVID-19 PATIENTS.","BACKGROUND: Many of the drugs being used in the treatment of the ongoing pandemic coronavirus disease 2019 (COVID-19) are associated with QT prolongation. Expert guidance supports ECG monitoring to optimize patient safety. OBJECTIVE: To establish an enhanced process for ECG monitoring of patients being treated for COVID-19. METHODS: We created an SBAR (Situation Background Assessment Recommendation Tool) identifying the indication for ECGs in COVID-19 patients, and tagged these ECGs to ensure prompt over reading and identification of those with QT prolongation (QTc >470 ms for QRS < 120 ms, QTc > 500 ms for QRS > 120 ms). This triggered a phone call from the electrophysiology service to the primary team to provide management guidance and a formal consultation if requested. RESULTS: During a 2-week period we reviewed 2006 ECGs, corresponding to 524 unique patients, of whom 103 (19.7%) met SBAR defined criteria for QT prolongation. When compared to those without QT prolongation, these patients were more often in the intensive care unit (58.3% vs 35.4%) and more likely to be intubated (31.1 vs 18.1%). Fifty patients with QT prolongation (48.5%) had electrolyte abnormalities, 98 (95.1%) were on COVID-19 related QT prolonging medications, and 62 (60.2%) were on 1-4 additional non COVID-19 related QT prolonging drugs. Electrophysiology recommendations were given to limit modifiable risk factors. No patient developed torsade de pointes. CONCLUSION: This process functioned efficiently, identified a high percentage of patients with QT prolongation, and led to relevant interventions. Arrhythmias were rare. No patient developed torsade de pointes.","Heart Rhythm","Jain, Shashank","Workman, Virginia","Ganeshan, Raj","Obasare, Edinrin R","Burr, Alicia","DeBiasi, Ralph M","Freeman, James V","Akar, Joseph","Lampert, Rachel","Rosenfeld, Lynda E","32387247"],"abstract":["BACKGROUND: Many of the drugs being used in the treatment of the ongoing pandemic coronavirus disease 2019 (COVID-19) are associated with QT prolongation. Expert guidance supports ECG monitoring to optimize patient safety. OBJECTIVE: To establish an enhanced process for ECG monitoring of patients being treated for COVID-19. METHODS: We created an SBAR (Situation Background Assessment Recommendation Tool) identifying the indication for ECGs in COVID-19 patients, and tagged these ECGs to ensure prompt over reading and identification of those with QT prolongation (QTc >470 ms for QRS < 120 ms, QTc > 500 ms for QRS > 120 ms). This triggered a phone call from the electrophysiology service to the primary team to provide management guidance and a formal consultation if requested. RESULTS: During a 2-week period we reviewed 2006 ECGs, corresponding to 524 unique patients, of whom 103 (19.7%) met SBAR defined criteria for QT prolongation. When compared to those without QT prolongation, these patients were more often in the intensive care unit (58.3% vs 35.4%) and more likely to be intubated (31.1 vs 18.1%). Fifty patients with QT prolongation (48.5%) had electrolyte abnormalities, 98 (95.1%) were on COVID-19 related QT prolonging medications, and 62 (60.2%) were on 1-4 additional non COVID-19 related QT prolonging drugs. Electrophysiology recommendations were given to limit modifiable risk factors. No patient developed torsade de pointes. CONCLUSION: This process functioned efficiently, identified a high percentage of patients with QT prolongation, and led to relevant interventions. Arrhythmias were rare. No patient developed torsade de pointes."],"journal":"Heart Rhythm","authors":["Jain, Shashank","Workman, Virginia","Ganeshan, Raj","Obasare, Edinrin R","Burr, Alicia","DeBiasi, Ralph M","Freeman, James V","Akar, Joseph","Lampert, Rachel","Rosenfeld, Lynda E"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32387247","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.hrthm.2020.04.047","keywords":["covid-19","ecg","hydroxychloroquine","qt prolongation","torsade de pointe"],"topics":["Treatment"],"weight":1,"_version_":1666428892696543232,"score":241.34625},{"pmid":32244059,"pmcid":"PMC7156157","title":"SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes.","text":["SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes.","Ever since the first case was reported at the end of 2019, the severe acute respiratory syndrome coronavirus 2 virus and associated lung disease coronavirus disease 2019 (COVID-19) has spread throughout the world and has become a pandemic. In particular, the high transmission rate of the virus has made it a threat to public health globally. Currently, there is no proven effective therapy against the virus, and the effect on other diseases is also uncertain, especially inherited arrhythmia syndrome. An arrhythmogenic effect of COVID-19 can be expected, potentially contributing to disease outcome. This may be of importance for patients with an increased risk of cardiac arrhythmias, either secondary to acquired conditions or comorbidities or consequent to inherited syndromes. Management of patients with inherited arrhythmia syndromes such as long QT syndrome, Brugada syndrome, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia in the setting of the COVID-19 pandemic may prove particularly challenging. Depending on the inherited defect involved, these patients may be susceptible to proarrhythmic effects of COVID-19-related issues such as fever, stress, electrolyte disturbances, and use of antiviral drugs. Here, we describe the potential COVID-19-associated risks and therapeutic considerations for patients with distinct inherited arrhythmia syndromes and provide recommendations, pending local possibilities, for their monitoring and management during this pandemic.","Heart Rhythm","Wu, Cheng-I","Postema, Pieter G","Arbelo, Elena","Behr, Elijah R","Bezzina, Connie R","Napolitano, Carlo","Robyns, Tomas","Probst, Vincent","Schulze-Bahr, Eric","Remme, Carol Ann","Wilde, Arthur A M","32244059"],"abstract":["Ever since the first case was reported at the end of 2019, the severe acute respiratory syndrome coronavirus 2 virus and associated lung disease coronavirus disease 2019 (COVID-19) has spread throughout the world and has become a pandemic. In particular, the high transmission rate of the virus has made it a threat to public health globally. Currently, there is no proven effective therapy against the virus, and the effect on other diseases is also uncertain, especially inherited arrhythmia syndrome. An arrhythmogenic effect of COVID-19 can be expected, potentially contributing to disease outcome. This may be of importance for patients with an increased risk of cardiac arrhythmias, either secondary to acquired conditions or comorbidities or consequent to inherited syndromes. Management of patients with inherited arrhythmia syndromes such as long QT syndrome, Brugada syndrome, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia in the setting of the COVID-19 pandemic may prove particularly challenging. Depending on the inherited defect involved, these patients may be susceptible to proarrhythmic effects of COVID-19-related issues such as fever, stress, electrolyte disturbances, and use of antiviral drugs. Here, we describe the potential COVID-19-associated risks and therapeutic considerations for patients with distinct inherited arrhythmia syndromes and provide recommendations, pending local possibilities, for their monitoring and management during this pandemic."],"journal":"Heart Rhythm","authors":["Wu, Cheng-I","Postema, Pieter G","Arbelo, Elena","Behr, Elijah R","Bezzina, Connie R","Napolitano, Carlo","Robyns, Tomas","Probst, Vincent","Schulze-Bahr, Eric","Remme, Carol Ann","Wilde, Arthur A M"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32244059","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.hrthm.2020.03.024","keywords":["brugada syndrome","covid-19","catecholaminergic polymorphic ventricular tachycardia","long qt syndrome","sars-cov-2","short qt syndrome"],"locations":["Brugada"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138492117188608,"score":238.58609},{"pmid":32407884,"title":"QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin.","text":["QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin.","BACKGROUND: There is no known effective therapy for patients with COVID-19. Initial reports suggesting the potential benefit of Hydroxychloroquine/Azithromycin (HY/AZ) have resulted in massive adoption of this combination worldwide. However, while the true efficacy of this regimen is unknown, initial reports have raised concerns regarding the potential risk of QT prolongation and induction of torsade de pointes (TdP). OBJECTIVE: to assess the change in QTc interval and arrhythmic events in patients with COVID-19 treated with HY/AZ METHODS: This is a retrospective study of 251 patients from two centers, diagnosed with COVID-19 and treated with HY/AZ. We reviewed ECG tracings from baseline and until 3 days after completion of therapy to determine the progression of QTc and incidence of arrhythmia and mortality. RESULTS: QTc prolonged in parallel with increasing drug exposure and incompletely shortened after its completion. Extreme new QTc prolongation to > 500 ms, a known marker of high risk for TdP had developed in 23% of patients. One patient developed polymorphic ventricular tachycardia (VT) suspected as TdP, requiring emergent cardioversion. Seven patients required premature termination of therapy. The baseline QTc of patients exhibiting extreme QTc prolongation was normal. CONCLUSION: The combination of HY/AZ significantly prolongs the QTc in patients with COVID-19. This prolongation may be responsible for life threating arrhythmia in the form of TdP. This risk mandates careful consideration of HY/AZ therapy in lights of its unproven efficacy. Strict QTc monitoring should be performed if the regimen is given.","Heart Rhythm","Chorin, Ehud","Wadhwani, Lalit","Magnani, Silvia","Dai, Matthew","Shulman, Eric","Nadeau-Routhier, Charles","Knotts, Robert","Bar-Cohen, Roi","Kogan, Edward","Barbhaiya, Chirag","Aizer, Anthony","Holmes, Douglas","Bernstein, Scott","Spinelli, Michael","Park, David S","Stefano, Carugo","Chinitz, Larry A","Jankelson, Lior","32407884"],"abstract":["BACKGROUND: There is no known effective therapy for patients with COVID-19. Initial reports suggesting the potential benefit of Hydroxychloroquine/Azithromycin (HY/AZ) have resulted in massive adoption of this combination worldwide. However, while the true efficacy of this regimen is unknown, initial reports have raised concerns regarding the potential risk of QT prolongation and induction of torsade de pointes (TdP). OBJECTIVE: to assess the change in QTc interval and arrhythmic events in patients with COVID-19 treated with HY/AZ METHODS: This is a retrospective study of 251 patients from two centers, diagnosed with COVID-19 and treated with HY/AZ. We reviewed ECG tracings from baseline and until 3 days after completion of therapy to determine the progression of QTc and incidence of arrhythmia and mortality. RESULTS: QTc prolonged in parallel with increasing drug exposure and incompletely shortened after its completion. Extreme new QTc prolongation to > 500 ms, a known marker of high risk for TdP had developed in 23% of patients. One patient developed polymorphic ventricular tachycardia (VT) suspected as TdP, requiring emergent cardioversion. Seven patients required premature termination of therapy. The baseline QTc of patients exhibiting extreme QTc prolongation was normal. CONCLUSION: The combination of HY/AZ significantly prolongs the QTc in patients with COVID-19. This prolongation may be responsible for life threating arrhythmia in the form of TdP. This risk mandates careful consideration of HY/AZ therapy in lights of its unproven efficacy. Strict QTc monitoring should be performed if the regimen is given."],"journal":"Heart Rhythm","authors":["Chorin, Ehud","Wadhwani, Lalit","Magnani, Silvia","Dai, Matthew","Shulman, Eric","Nadeau-Routhier, Charles","Knotts, Robert","Bar-Cohen, Roi","Kogan, Edward","Barbhaiya, Chirag","Aizer, Anthony","Holmes, Douglas","Bernstein, Scott","Spinelli, Michael","Park, David S","Stefano, Carugo","Chinitz, Larry A","Jankelson, Lior"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32407884","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.hrthm.2020.05.014","keywords":["azithromycin","covid-19","hydroxychloroquine","qt interval","torsade de pointes"],"topics":["Treatment"],"weight":1,"_version_":1666802845593108480,"score":234.31802}]}